The median time to treatment initiation across all cancer types increased from 21 days in 2004 to 28 days in 2015. The median time to treatment initiation is increasing across cancer types, and this ...

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

We need to rethink our approach in responding to cancers in our younger women patients,” said Hope S. Rugo, MD.